Filtered By:
Condition: Atrial Fibrillation
Countries: Denmark Health

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 102 results found since Jan 2013.

Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry.
CONCLUSION:  Presence, but not extent, of CAD was an independent risk factor of the composite thromboembolic endpoint beyond the components already included in the CHA2DS2-VASc score. Consequently, we suggest that significant angiographically proven CAD should be included in the vascular disease criterion in the CHA2DS2-VASc score. PMID: 30419601 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 12, 2018 Category: Hematology Authors: Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, Bøtker HE, Lip GYH, Maeng M Tags: Thromb Haemost Source Type: research

New-onset atrial fibrillation after PCI and CABG for left main disease: insights from the EXCEL trial and additional studies
Purpose of review To provide an up-to-date review of recent trials examining the incidence and prognostic impact of new-onset atrial fibrillation (NOAF) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) and the impact of postprocedural NOAF compared to nonsurgical atrial fibrillation. Recent findings A recent analysis from the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial demonstrated that NOAF is much more frequent following surgical compared with percut...
Source: Current Opinion in Cardiology - October 11, 2018 Category: Cardiology Tags: ISCHEMIC HEART DISEASE: Edited by Peter H. Stone Source Type: research

Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.
Conclusion: Variation in published AF stroke rates for patients not receiving anticoagulant therapy results in multifold variation in the net clinical benefit of anticoagulation. Guidelines should better reflect the uncertainty in current thresholds of stroke risk score for recommending anticoagulation. Primary Funding Source: None. PMID: 30264130 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - September 25, 2018 Category: Internal Medicine Authors: Shah SJ, Eckman MH, Aspberg S, Go AS, Singer DE Tags: Ann Intern Med Source Type: research

Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study
Atrial fibrillation is a common cause of stroke, and diabetes increases stroke risk. Stroke risk may vary depending on the type of diabetes. We investigated whether type 1 and type 2 diabetes are associated with different risks of thromboembolism among patients with atrial fibrillation.
Source: International Journal of Cardiology - July 22, 2018 Category: Cardiology Authors: Mia V. Fangel, Peter B. Nielsen, Torben B. Larsen, Bo Christensen, Thure F. Overvad, Gregory Y.H. Lip, Samuel Z. Goldhaber, Martin B. Jensen Source Type: research

Abstract 4: Variation in Published Stroke Rates Results in Wide Variation in the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation Session Title: QCOR 2018 Young Investigator Award Finalists
Conclusion: Using current guidelines, variation in published off-anticoagulation stroke rates results in tenfold variation in the estimated net clinical benefit of anticoagulation. Guidelines should better reflect the uncertainty of the current approach that uses a CHA2DS2-VASc threshold to recommend anticoagulation.
Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Shah, S. J., Eckman, M. H., Aspberg, S., Go, A. S., Singer, D. E. Tags: Session Title: QCOR 2018 Young Investigator Award Finalists Source Type: research

Effectiveness of Screening Postmenopausal Women for Cardiovascular Diseases: A Population Based, Prospective Parallel Cohort Study.
CONCLUSIONS: This multifaceted screening offer to a general population sample of postmenopausal women had no effects on all cause mortality or hospital admission for MI, IHD, PAD, and stroke within a short-term follow up period. PMID: 29625727 [PubMed - as supplied by publisher]
Source: PubMed: Eur J Vasc Endovasc ... - April 3, 2018 Category: Surgery Authors: Dahl M, Søgaard R, Frost L, Høgh A, Lindholt J Tags: Eur J Vasc Endovasc Surg Source Type: research

Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban.
Abstract Real-world data are a well-recognized component within the drug lifecycle, and such data are generated from a range of sources and study designs, including claims databases, electronic health records, non-interventional studies (NIS) and registries. While this information can be of vital clinical importance, there may be challenges in understanding the relevance of the differing study designs, endpoints and populations. Here, we summarize the value of real-world evidence and considerations pertinent to their use in clinical research. Owing to the variety of analyses being conducted using real-world data, ...
Source: Thrombosis and Haemostasis - March 22, 2018 Category: Hematology Authors: Camm AJ, Coleman CI, Larsen TB, Nielsen PB, Tamayo CS Tags: Thromb Haemost Source Type: research

Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc?
CONCLUSIONS: Female sex is a risk modifier for stroke in patients with atrial fibrillation. Initial decisions on oral anticoagulant treatment could be guided by a CHA2DS2-VA score (ie, excluding the sex category criterion), but the Sc risk component modifies and accentuates stroke risk in women who would have been eligible for oral anticoagulant treatment on the basis of ≥2 additional stroke risk factors. PMID: 29459469 [PubMed - in process]
Source: Circulation - February 20, 2018 Category: Cardiology Authors: Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH Tags: Circulation Source Type: research

Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study
ConclusionAF patients resuming VKA and NOAC treatment following traumatic injury have lower hazard of all-cause mortality and ischaemic stroke, increased hazard of major bleeding but without additional hazards of recurrent traumatic injury. Withholding OAC following a traumatic injury in AF patients may not be warranted.
Source: European Heart Journal - November 18, 2017 Category: Cardiology Source Type: research

Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study
ConclusionsCompared with patients without CKD, among incident heart failure patients without atrial fibrillation, CKD both with and without dialysis was associated with a higher rate of major bleeding and all‐cause death. Only CKD‐no RRT was associated with a higher rate of ischaemic stroke and intracranial bleeding.
Source: ESC Heart Failure - November 1, 2017 Category: Cardiology Authors: Line Melgaard, Thure Filskov Overvad, Flemming Skj øth, Jeppe Hagstrup Christensen, Torben Bjerregaard Larsen, Gregory Y.H. Lip Tags: Original Research Article Source Type: research

Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011 –2016
We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.
Source: Thrombosis Research - October 16, 2017 Category: Hematology Authors: Alexandar Dukanovic, Laila Staerk, Emil Loldrup Fosb øl, Kasper Gadsbøll, Gunnar Hilmar Gislason, Jonas Bjerring Olesen Tags: Full Length Article Source Type: research

Long-Term Exposure to Road Traffic Noise and Nitrogen Dioxide and Risk of Heart Failure: A Cohort Study
Conclusions: Long-term exposure to NO2 and road traffic noise was associated with higher risk of heart failure, mainly among men, in both single- and two-pollutant models. High exposure to both pollutants was associated with highest risk. https://doi.org/10.1289/EHP1272 Received: 25 October 2016 Revised: 09 August 2017 Accepted: 09 August 2017 Published: 26 September 2017 Address correspondence to M. Sørensen. Diet, Genes and Environment, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark. Telephone: +45 35257626. Email: mettes@cancer.dk Supplemental Material is available online (https://doi.org/1...
Source: EHP Research - September 26, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
ConclusionsStandard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.
Source: Journal of Internal Medicine - September 21, 2017 Category: Internal Medicine Authors: L. Staerk, T. A. Gerds, G. Y. H. Lip, B. Ozenne, A. N. Bonde, M. Lamberts, E. L. Fosb øl, C. Torp‐Pedersen, G. H. Gislason, J. B. Olesen Tags: Original Article Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Important factors affecting the choice of an oral anticoagulant may be missed in database studies
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - September 7, 2017 Category: Internal Medicine Authors: Emma Aarnio, Risto Huupponen, Maarit Jaana Korhonen Tags: Letter to the Editor Source Type: research